Pharmigene, Inc. (TPEX:7595)
Taiwan · Delayed Price · Currency is TWD 7.42
+0.07 (0.95%)
Aug 19, 2026, 11:57 AM CST
Pharmigene Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 187.88 | 199.89 | 116.53 | 132.71 | 133.8 | 129.35 | |
Revenue Growth | 25.88% | 71.53% | -12.19% | -0.82% | 3.44% | 27.63% |
Cost of Revenue | 135.25 | 143.46 | 75.06 | 90.17 | 89.07 | 83.31 |
Gross Profit | 52.63 | 56.43 | 41.47 | 42.54 | 44.73 | 46.05 |
Selling, General & Admin | 74.06 | 72.39 | 93.13 | 71.32 | 58.9 | 54.73 |
Research & Development | 26.04 | 40.64 | 29.63 | 30.34 | 29.69 | 15.49 |
Operating Expenses | 97.45 | 111.39 | 126.7 | 101.73 | 89.18 | 68.78 |
Operating Income | -44.82 | -54.96 | -85.23 | -59.19 | -44.45 | -22.74 |
Interest Expense | -14.42 | -14.44 | -12.08 | -7.91 | -0.2 | -0.31 |
Interest & Investment Income | 0.84 | 1.01 | 1.07 | 1.69 | 1.5 | 0.68 |
Earnings From Equity Investments | -0.2 | -0.35 | -4.51 | -4.6 | -0.72 | -1.44 |
Currency Exchange Gain (Loss) | -0.48 | -0.48 | -0.05 | -0.23 | -0.22 | -0.39 |
Other Non Operating Income (Expenses) | 14.27 | 3.69 | 3.51 | 0.17 | 0.75 | 0.42 |
EBT Excluding Unusual Items | -44.81 | -65.52 | -97.29 | -70.07 | -43.35 | -23.77 |
Gain (Loss) on Sale of Investments | -2.46 | -2.46 | 14.46 | -0.51 | 0.21 | - |
Gain (Loss) on Sale of Assets | - | - | - | - | 0.4 | - |
Asset Writedown | -5 | -5 | - | -2.05 | - | - |
Other Unusual Items | - | - | - | - | 0.03 | - |
Pretax Income | -52.26 | -72.97 | -82.83 | -72.63 | -42.71 | -23.77 |
Income Tax Expense | 0 | 0.03 | 0.04 | 0.02 | 0.01 | -0.34 |
Net Income | -52.27 | -73 | -82.86 | -72.65 | -42.72 | -23.43 |
Net Income to Common | -52.27 | -73 | -82.86 | -72.65 | -42.72 | -23.43 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 50 | 50 | 50 | 45 | 43 | 43 |
Shares Outstanding (Diluted) | 50 | 50 | 50 | 45 | 43 | 43 |
Shares Change | -0.10% | - | 10.96% | 4.63% | - | 28.48% |
EPS (Basic) | -1.04 | -1.45 | -1.64 | -1.60 | -0.98 | -0.54 |
EPS (Diluted) | -1.04 | -1.45 | -1.64 | -1.60 | -0.98 | -0.54 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -6.38 | -75.33 | -109.42 | -742.85 | -33.96 | -31.98 |
Free Cash Flow Per Share | -0.13 | -1.49 | -2.17 | -16.33 | -0.78 | -0.74 |
Gross Margin | 28.01% | 28.23% | 35.59% | 32.06% | 33.43% | 35.60% |
Operating Margin | -23.86% | -27.49% | -73.13% | -44.60% | -33.22% | -17.58% |
Profit Margin | -27.82% | -36.52% | -71.11% | -54.74% | -31.92% | -18.12% |
Free Cash Flow Margin | -3.40% | -37.69% | -93.90% | -559.76% | -25.38% | -24.72% |
EBITDA | -25.47 | -34.16 | -65.21 | -43.19 | -31.67 | -14.63 |
EBITDA Margin | -13.56% | -17.09% | -55.96% | -32.55% | -23.67% | -11.31% |
D&A For EBITDA | 19.35 | 20.8 | 20.01 | 15.99 | 12.78 | 8.1 |
EBIT | -44.82 | -54.96 | -85.23 | -59.19 | -44.45 | -22.74 |
EBIT Margin | -23.86% | -27.49% | -73.13% | -44.60% | -33.22% | -17.58% |